The Unique Device Identification (UDI) system is a key regulatory tool for traceability across the full lifecycle of medical devices. As markets such as the United States, the European Union, South Korea and Saudi Arabia have gradually built UDI regulatory frameworks, a growing number of countries now require medical device manufacturers to mark UDI on product labels and submit related product information to official databases.
Based on publicly available regulations, notices and official implementation timelines from national regulatory authorities, this article reviews the markets that have completed fully mandatory UDI implementation for all risk classes.
1. Criteria for Determining Fully Mandatory UDI Implementation
Before comparing national UDI implementation, it is important to clarify that UDI is not just a QR code or barcode printed on product packaging.
A complete UDI system typically covers the following elements:
| Element | Specific requirement |
|---|---|
| UDI-DI | The product identifier, used to identify a specific product model or specification from a specific manufacturer |
| UDI-PI | The production identifier, covering the lot number, serial number, manufacture date, expiry date and other applicable information |
| UDI labeling | Carrying the UDI carrier on the device itself, the label or the packaging |
| Database submission | Submitting the UDI-DI and corresponding product information to the database designated by the regulatory authority |
| Direct marking | Permanently marking the UDI on the device itself for qualifying reusable medical devices |
| Data maintenance | Updating UDI information as required when product information, models or packaging specifications change |
2. Countries That Have Completed Fully Mandatory UDI Implementation for All Applicable Risk Classes
Based on the official regulations and implementation notices that can currently be verified, the following three countries clearly fall within this scope.
1. United States: FDA
Full implementation timeline: phased UDI labeling and database implementation for all risk classes was completed in 2018, and the direct marking deadline for applicable Class I devices was completed in 2020.
The United States was one of the earliest countries to establish a mandatory UDI regulatory framework.
Regulatory basis:
- Section 519(f) of the Federal Food, Drug, and Cosmetic Act.
- 21 CFR Part 801, Subpart B.
- 21 CFR Part 830.
- FDA Final Rule: Unique Device Identification System, issued on September 24, 2013.
UDI implementation scope and timeline:
| Product category | UDI labeling and database implementation date |
|---|---|
| Class III | September 24, 2014 |
| Implantable, life-supporting and life-sustaining devices | September 24, 2015 |
| Class II | September 24, 2016 |
| Class I and unclassified devices subject to UDI requirements | September 24, 2018 |
The dates above are the main implementation milestones set out in FDA regulations.
For reusable devices requiring direct marking, separate deadlines apply:
- Class III: September 24, 2016.
- Class II: September 24, 2018.
- Class I: September 24, 2020.
FDA subsequently issued enforcement policies for the labeling and GUDID data submission of certain Class I devices, deferring enforcement of some requirements to September 24, 2022 and December 8, 2022 respectively.
Key implementation requirements:
- The labels and packages of devices subject to the requirements must carry the UDI.
- The UDI consists of a UDI-DI and a UDI-PI.
- Product information must be submitted to the FDA’s GUDID database as required.
- Devices meeting the reuse and reprocessing criteria must also be directly marked.
- Exemptions and alternative approaches applicable to a product must follow the relevant FDA regulations.
2. South Korea: MFDS
Full implementation date: July 1, 2022.
South Korea implemented UDI in phases by device risk class, with the last group of Class 1 medical devices entering mandatory implementation from July 1, 2022.
Regulatory basis:
- Medical Devices Act.
- Article 20(8) of the Medical Devices Act.
- Article 31-3 of the Medical Devices Act.
- Enforcement Rule of the Medical Devices Act.
- MFDS Notice No. 2023-67: Guidelines on the Labeling and Management of Standard Codes for Medical Devices.
South Korea’s UDI system requires not only product identification but also the entry of related product information into the medical device comprehensive information system.
UDI implementation timeline:
| Risk class | Mandatory implementation date | Status |
|---|---|---|
| Class 4 | July 1, 2019 | Implemented |
| Class 3 | July 1, 2020 | Implemented |
| Class 2 | July 1, 2021 | Implemented |
| Class 1 | July 1, 2022 | Implemented |
Key implementation requirements:
- Medical device containers or outer packaging must be labeled with the standard code as required.
- The standard code consists of a UDI-DI and a UDI-PI.
- Manufacturers and importers must register product information in the medical device comprehensive information system as required.
- Product information must be updated as required whenever it changes.
- Supply information reporting follows its own phased schedule, with the last group of Class 1 supply information reporting taking effect from July 1, 2023.
South Korea’s UDI system also covers in vitro diagnostic medical devices, with applicability governed by the In Vitro Diagnostic Medical Devices Act and its supporting regulations.
3. Saudi Arabia: SFDA
Full implementation date: September 1, 2024.
Saudi Arabia has completed fully mandatory UDI implementation for all risk classes from Class A through Class D.
The Saudi UDI system was established by the Saudi Food and Drug Authority (SFDA) and is administered through the Saudi-DI database.
Regulatory basis:
- MDS-REQ-007-V4/220524: Requirements for Unique Device Identification (UDI) for Medical Devices.
- MDS-CIR-002-V2/220624: circular adjusting the UDI implementation timeline.
- Relevant provisions of the Medical Devices Law and its Implementing Regulations.
UDI implementation timeline:
| Risk class | Risk classification | Mandatory implementation date |
|---|---|---|
| Class D | High risk | September 1, 2023 |
| Class C | Medium-to-high risk | September 1, 2023 |
| Class B | Medium-to-low risk | September 1, 2023 |
| Class A | Low risk | September 1, 2024 |
Scope of UDI implementation:
The SFDA’s UDI requirements apply to medical devices, medical supplies and their accessories intended for the Saudi market that are not exempt from marketing authorization requirements.
Key requirements include:
- Manufacturers must create UDIs in accordance with the standards of accredited issuing agencies, including GS1, HIBCC and ICCBBA.
- The UDI consists of a UDI-DI and a UDI-PI.
- The primary product label and higher packaging levels must be labeled with the UDI as required.
- The UDI must be provided both as human-readable information (HRI) and as an automatic identification and data capture (AIDC) carrier.
- The manufacturer or its authorized representative must submit and maintain product information in the Saudi-DI database.
- Qualifying reusable devices must also be directly marked on the device itself.
For products imported before the relevant mandatory deadline, SFDA circulars also provide transition arrangements for selling existing inventory after the deadline.
3. Summary of Global UDI Implementation
| Implementation status | Country/region | Key facts |
|---|---|---|
| Fully mandatory core UDI implementation completed for all applicable risk classes | United States | Class I to Class III labeling and database implementation completed in phases |
| Fully mandatory core UDI implementation completed for all applicable risk classes | South Korea | Class 1 to Class 4 mandatory implementation completed |
| Fully mandatory core UDI implementation completed for all applicable risk classes | Saudi Arabia | Class A to Class D mandatory implementation completed |
4. Practical Implications for Medical Device Manufacturers
UDI has become a major regulatory requirement in many leading medical device markets. Manufacturers planning global registrations are advised to factor UDI into product design, registration and launch preparation from the outset.
1. Establish a UDI coding management system early
Manufacturers should set up a unified UDI coding management mechanism that clearly maps the relationships between UDI-DIs, UDI-PIs, packaging levels and different product models.
2. Pay attention to product labeling and packaging levels
Different markets may impose different requirements on UDI placement, packaging levels, barcode formats, HRI and AIDC.
In particular, for reusable devices manufacturers need to additionally confirm whether direct marking requirements apply.
3. Integrate UDI into global regulatory documentation management
Manufacturers are advised to add a UDI management module to their global regulatory documentation repository and keep it continuously updated with:
- Product UDI-DIs and UDI-PIs.
- Issuing agencies and coding rules.
- Registration status in each country’s UDI database.
- Product label and packaging versions.
- Direct marking requirements.
- Implementation deadlines and exemptions in each country.
This helps reduce duplicate code assignment, labeling rework and inconsistent database information when products enter different national markets.
Official sources
- US FDA – Unique Device Identification System (UDI)
- US FDA – Global Unique Device Identification Database (GUDID)
- South Korea MFDS
- Saudi Food and Drug Authority (SFDA)
This article is based on publicly available regulations, notices and implementation timelines published by the US FDA, South Korea’s MFDS and Saudi Arabia’s SFDA, including 21 CFR Parts 801 and 830, MFDS Notice No. 2023-67, and SFDA MDS-REQ-007-V4 and MDS-CIR-002-V2. Information is current as of November 9, 2026. It is provided for industry communication and reference only and does not constitute legal or regulatory advice; specific requirements are subject to the latest official texts published by the relevant regulatory authorities.